Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|13|2253-2261

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.13, 2015-07, pp. : 2253-2261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 347-352

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3024-3031

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Phase II Study Comparing Two Schedules of the 21-Day Regimen of Gemcitabine and Carboplatin in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 267-270

Karger

Access to resources Recommend Favorite

A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 333-341

Karger

Access to resources Recommend Favorite